Bioventus Inc.
BVS
$7.51
-$0.09-1.14%
NASDAQ
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.58% | 5.08% | 8.60% | 11.89% | 10.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58% | 5.08% | 8.60% | 11.89% | 10.40% |
| Cost of Revenue | -0.76% | 1.71% | 2.61% | 0.49% | -1.87% |
| Gross Profit | 2.73% | 6.77% | 11.75% | 18.29% | 17.65% |
| SG&A Expenses | -1.54% | 3.03% | 7.89% | 8.89% | 6.53% |
| Depreciation & Amortization | -22.39% | -16.67% | -11.55% | -13.46% | -3.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.85% | 2.20% | 5.88% | 5.33% | 2.69% |
| Operating Income | 68.05% | 64.68% | 76.69% | 1,664.26% | 341.06% |
| Income Before Tax | 119.44% | 102.94% | -89.24% | 57.02% | 58.18% |
| Income Tax Expenses | 132.76% | 131.68% | -653.16% | -6,327.06% | 34.90% |
| Earnings from Continuing Operations | 117.81% | 99.62% | -58.59% | 61.41% | 59.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -114.81% | -102.16% | 80.09% | -55.55% | -60.60% |
| Net Income | 118.70% | 98.87% | -53.12% | 77.03% | 77.02% |
| EBIT | 68.05% | 64.68% | 76.69% | 1,664.26% | 341.06% |
| EBITDA | 20.77% | 16.46% | 15.67% | 44.84% | 25.19% |
| EPS Basic | 117.90% | 98.67% | -49.74% | 77.72% | 77.69% |
| Normalized Basic EPS | 53.87% | 46.24% | 229.03% | 3,782.50% | 132.92% |
| EPS Diluted | 117.53% | 98.22% | -50.00% | 77.68% | 77.66% |
| Normalized Diluted EPS | 49.80% | 41.72% | 229.03% | 3,782.50% | 132.92% |
| Average Basic Shares Outstanding | 3.55% | 3.89% | 3.54% | 3.01% | 2.55% |
| Average Diluted Shares Outstanding | 5.10% | 4.69% | 3.54% | 3.01% | 2.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |